Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Nature in Genome Medicine
- Vol. 4 (6) , 52
Abstract
Antidepressants are among the most commonly prescribed drugs, and a range of medications are available. However, treatment response to a particular drug varies greatly between patients, with only 30% of patients responding well to the first treatment administered. Given evidence that antidepressant treatment response is a heritable trait, together with technological advances in genetic research, three recently published genome-wide investigations into antidepressant responses have examined the determinants of variability in treatment outcomes between depressed patients. Here, we review these studies within the context of wider research efforts to identify treatment response predictors. Some interesting genes have been implicated, but no variants have yet been robustly and reliably linked to response. This may suggest that genetic effect sizes are smaller than originally anticipated. Candidate gene approaches in these samples have lent support to the involvement of serotonergic, glutamatergic and stress-response systems in treatment response, although corroborative evidence from genome-wide analyses indicates these results should be interpreted cautiously. Closer examination of antidepressant response, considering it as a complex trait, has indicated that multiple genes of small effect are likely to be involved. Furthermore, there is some evidence that genetic influence on response to treatment may vary between patients with different symptom profiles or environmental exposures. This has implications for the translation of pharmacogenetic findings into clinical practice: genotypic information from multiple loci and data on non-genetic factors are likely to be needed to tailor antidepressant treatment to the individual patient.Keywords
This publication has 73 references indexed in Scilit:
- Ketamine as a Novel Antidepressant: From Synapse to BehaviorClinical Pharmacology & Therapeutics, 2011
- Therapygenetics: the 5HTTLPR and response to psychological therapyMolecular Psychiatry, 2011
- Is Depression an Inflammatory Disorder?Current Psychiatry Reports, 2011
- Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptylineJournal of Affective Disorders, 2011
- Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic RegionBiological Psychiatry, 2010
- A Genomewide Association Study of Citalopram Response in Major Depressive DisorderBiological Psychiatry, 2010
- Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant TreatmentNeuropsychopharmacology, 2009
- SLC6A4 variation and citalopram responseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008
- The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) CohortBiological Psychiatry, 2008
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersNature Reviews Drug Discovery, 2008